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ak Lawn, Illinois; and Dallas, Texas
The failing heart is not just an enlarged version of the
normal heart.
Louis N. Katz (1)
n 1981, de Bold et al. (2) described a potent diuretic and
atriuretic factor derived from the atrial extracts of rats.
ubsequent research has led to the characterization of a
amily of peptides now known as natriuretic peptides. With
he emerging understanding of the natriuretic peptide
ystem has come the hope of enhanced diagnosis, more
xact prognostication, and novel therapy for the heart failure
yndrome (3,4). As with any “work in progress,” the status
f each of these hopes waxes and wanes, but few new
oncepts or therapies have realized both the enthusiasm and
he rancor experienced by natriuretic peptides.
See page 1835
cute Decompensated Heart Failure
he primary therapeutic target for natriuretic peptides has
een acute decompensated heart failure (ADHF), a rela-
ively new addition to the vernacular of heart failure. We
ave come to define ADHF as new-onset heart failure or
ore likely worsening of a patient’s chronic, well-
stablished heart failure that requires hospitalization or
rgent care. Demographics have been described, and a
atural history has been determined. But especially with
egard to worsening of chronic heart failure, is this process
ruly an acute one or is it an expected consequence of the
nexorable decline of a chronic insidious maladaptive state of
elicate heart, kidney, and vascular interactions? Indeed,
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Heart Failure Institute and the Department of Medicine, Advocate
hrist Medical Center, and the University of Illinois, Oak Lawn, Illinois; and the
Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas,w
exas. Dr. Yancy has received a research grant from and is a consultant for Scios.
r. Silver has received a research grant from Scios.here are perturbations in cardiac function that trigger and
ropagate this “decompensated” state (e.g., ischemia, ar-
hythmia, dietary indiscretions). However, the corollary
uggesting that there is a suddenness that could not have
een anticipated has perhaps been overstated.
Nevertheless, patients hospitalized with heart failure are
t increased risk for rehospitalization and near-term mor-
ality and a compelling unmet clinical need emerges.
The fallacy in the sojourn to identify effective therapies for
DHF has been the presumption that short-term administra-
ion of any agent over hours to days would significantly affect
onger-term outcomes over ensuing weeks, months, and years.
uch an effect would require profound efficacy with minimal
isk in a critically ill patient population. The recently reported
VEREST (Efficacy of Vasopressin Antagonism in Heart
ailure: Outcome Study With Tolvaptan) studies (5,6) clearly
emonstrate how difficult it is to impact death and rehospital-
zation after an episode of decompensated heart failure.
he Emergence of
atriuretic Peptides as Agents for ADHF
consistent observation in heart failure has been that the
evel of endogenous natriuretic peptide synthesis and release
arallels the severity of the heart failure syndrome. Despite
wide range of physiologic actions, including cardiac, renal,
emodynamic, antiremodeling, cytoprotective, and endocri-
ologic, a repeated observation has been that endogenous
atriuretic peptides fail to fully ameliorate the overwhelm-
ng effects of adverse neurohormonal activation in heart
ailure. The therapeutic use of natriuretic peptides, as
erived from recombinant technology, raised hope that
xogenous administration might further augment natriuretic
eptide activity and overcome the pathophysiological effects
f neurohormonal activation in heart failure.
Limited moderate-sized randomized clinical trials dem-
nstrating presumed safety and modest efficacy of nesiritide
B-type natriuretic peptide) led to Food and Drug Admin-
stration approval and introduction of nesiritide to the
reatment armamentarium of acute decompensated heart
ailure. The primary clinical role of nesiritide has been as a
asodilator added to diuretic therapy for patients with
ecompensated heart failure with symptoms of dyspnea at
est in the absence of hypotension. Because of the adverse
rognostic influence of concomitant renal disease in the
etting of heart failure, it was hoped that nesiritide would be
t least “friendly” to the kidney if not in fact renoprotective—
his “wish” was in part responsible for the dramatic uptake of
esiritide after its approval.
However, the validity of the benefits of nesiritide was
uickly called into question. In 2004, a small randomized,
ouble-blind, crossover trial of nesiritide versus placebo in
atients with ADHF found evidence of volume overload
nd recent worsened renal function failed to demonstrate
mprovement in renal function (7). Enthusiasm for nesiritide
as further tempered after the emergence of a meta-analysis
s
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Editorial Comment November 6, 2007:1841–3uggesting the possibility of worsening renal function in
atients who had been exposed to nesiritide. This was
mpacted yet again by a second meta-analysis suggesting an
ncreased risk of death 30 days after administration of
atriuretic peptides for ADHF (8,9). What has been needed
o corroborate or refute these concerns are prospective data
hat test the association of nesiritide use and the risk of
orsening renal function in an “at-risk” population.
The BNP-CARDS (B-Type Natriuretic Peptide in Car-
iorenal Decompensation Syndrome) trial is published in
his issue of the Journal (10). This study was a small,
ingle-center, randomized, placebo-controlled trial of 75
atients with baseline renal insufficiency and decompen-
ated heart failure given fixed-dose nesiritide versus placebo
ver the course of 48 h with a primary end point of adverse
hange in renal function. The authors’ findings are note-
orthy: “the main finding of this study was that in a cohort
f patients with baseline renal insufficiency and ADHF,
dministration of nesiritide in addition to standard therapy
id not result in worsened renal function. Importantly,
dministration of nesiritide did not protect against the
evelopment of renal dysfunction either.” It is important to
ote that the BNP-CARDS population was older, more
ikely to have preserved ejection fraction, and had lesser
cuity than the earlier patient populations. Importantly, a
olus was not consistently used in the BNP-CARDS study.
hese data are provocative but not nearly definitive due to
he small sample size, single-center experience, and lack of
ower to detect a change in important clinical outcomes.
Nevertheless, we believe that these observations, when
dded to other recent data, serve to mute, but not resolve,
oncerns regarding renal insufficiency related to the use of
atriuretic peptides. This quelling of our angst began with
he earlier report of the NAPA (Nesiritide Administered
eri-Anesthesia in Patients Undergoing Cardiac Surgery)
rial, where nesiritide given to patients with left ventricular
ysfunction demonstrated attenuation of renal dysfunction
ommonly found after cardiopulmonary bypass (11). More
ecently, the preliminary results of the FUSION II
Follow-Up Serial Infusions of Nesiritide in Advanced
eart Failure) study, a trial testing the safety and efficacy of
erial outpatient administration of nesiritide to patients with
dvanced heart failure, likewise failed to reveal evidence of
enal harm (12).
So, how do we synthesize the information before us? The
aradigm of natriuretic peptides remains provocative and
ontinues to offer both diagnostic and therapeutic promise.
owever, the natriuretic peptide system as intended in
ature is a homeostatic system operating at very low levels of
ynthesis and release. In patients with advanced heart failure,
he natriuretic peptide system is exaggerated and may even be
ysfunctional. Efforts to restore natriuretic peptide homeostasis
ith exogenous administration of nesiritide are reasonable,
lthough counterintuitive, to the usual paradigm of neurohor-
onal antagonism and with the awareness that unintendedonsequences of exogenous administration might occur. flearly, the administration of natriuretic peptides must be
arefully considered, and it is possible that our early forays into
he therapeutic application of natriuretic peptides may have
een flawed and should be revisited.
Nesiritide was originally tested at greater doses than are
urrently used, given consistently with a bolus and with
uch less regard for the adverse implications of hypoten-
ion, concomitant high dose diuretic therapy, and dynamic
hanges in renal function in the setting of decompensated
eart failure. It is likely perhaps that the earlier concerns of
enal harm reflect those incipient or flawed practices and are
ot now duplicated in contemporary datasets with carefully
anaged patient populations. Certainly, the questions re-
arding nesiritide are far from resolved and the large
SCEND HF (Acute Study of Clinical Effectiveness of
esiritide in Decompensated Heart Failure) trial needs to
roceed. However, pending new information, the current
ata make sense.
Patients with heart failure exist at the edge of a compen-
ated state, and minimal perturbances can result in “decom-
ensation.” It is not implausible for acute therapies to lack a
ramatic effect on outcomes, nor is it impossible to observe
dverse outcomes temporally related to an acute therapy and
o ascribe morbidity/mortality risks to that intervention. It is
lso quite possible that even naturally occurring compounds,
f used at nonphysiological doses, may provoke harm.
linical trials frequently resolve these issues, but the signif-
cant patient heterogeneity in the population of patients
ith ADHF has limited the generation of clear signals.
specially with regards to nesiritide, there have been im-
ortant background changes in the global management of
ecompensated heart failure and in a better understanding
f the natriuretic peptide paradigm; thus, the practice has
ndeed changed. The more recent prospective, randomized,
ouble-blind studies now being completed and reported,
ncluding NAPA, BNP-CARDS, and FUSION II, have
ssuaged some of our concerns of renal harm and refocused
he question on efficacy. We must however continue to
esolve the questions of safety while also continuing to
ursue the precise clinical role, ideal patient phenotype, and
easonable expectation of drug effect. Perhaps we have set
ur expectations too high; there is a progression of disease
long the continuum of heart failure that is irreversible.
hat point may, in fact, be the true “ADHF” phenotype
i.e., “advanced” rather than “acute” decompensated heart
ailure). If that is true, then our task at hand is earlier
dentification and treatment of the heart failure patient
efore the downward spiral begins.
May we suggest revisiting a lesson from Louis N. Katz
13): “the patient with heart failure does not just have an
nlarged version of the normal heart but rather a radically
eranged milieu which borders most of the time on the edge
f depleted reserves.” We ought not to expect most thera-
ies, even aggressive ones, to work all of the time, reverse
arget organ damage in most, or provide a “cure” to even a
ew. Certainly we should not apply this standard to a
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November 6, 2007:1841–3 Editorial Commenteptide system designed for homeostasis. As we do more
rials to further investigate natriuretic peptides, we must
esolve to better address the earlier stages of the heart failure
yndrome unravel the pathophysiology of decompensation,
nd study the role of earlier intervention with these peptides
n a more physiologic way. We should not yet dismiss the
atriuretic paradigm until we resolve the best practice.
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